Navigation Links
Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results
Date:3/23/2009

e webcast will be available at the same location through April 6, 2009.

In the event that any non-GAAP financial information is discussed on the conference call that is not described in this release, related complementary information will be made available on the Investor Relations page of the Company's website as soon as practical after the conclusion of the conference call.

About Transcept Pharmaceuticals, Inc.

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience. On January 30, 2009 Transcept completed a merger with Novacea, Inc. As part of the transaction, Novacea changed its name to "Transcept Pharmaceuticals, Inc." and its NASDAQ ticker symbol to "TSPT." The combined Company resources resulting from the merger are expected to enable Transcept to carry out its plans to commercialize its lead product candidate, Intermezzo(R). If approved, Intermezzo(R) is positioned to be the first commercially available sleep aid specifically for use in the middle of the night when patients awaken and have difficulty returning to sleep. Intermezzo(R) Phase 3 clinical trials have been completed and, on September 30, 2008, Transcept submitted an NDA to the FDA which subsequently assigned a PDUFA date of July 30, 2009 to the Intermezzo(R) NDA.

For further information, please visit the Company's website at: http://www.transcept.com.

Safe Harbor Statement

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future re
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results
2. Transcept Pharmaceuticals to Present at Two Upcoming Conferences
3. Transcept Pharmaceuticals, Inc. Completes Merger with Novacea, Inc.
4. Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel
5. Transcept Pharmaceuticals, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
6. Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
7. Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
8. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
9. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
10. Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
11. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... Research Institute at Virginia Mason (BRI) recently received a ... metastatic breast cancer reduces both the growth of primary ... have found in models of the disease that blocking ... percent and can keep the tumor from metastasizing or ... comes from the National Cancer Institute of the National ...
(Date:4/18/2014)... in French . ... and regenerative medicine. A team led by Ludwik Leibler ... Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire ... demonstrated that the principle of adhesion by aqueous solutions ... soft-tissue organs and tissues. This easy-to-use gluing method has ...
(Date:4/17/2014)... inflammation in non-cancerous prostate tissue may have nearly twice ... with no inflammation, according to results of a new ... Cancer Center. , The link between persistent inflammation and ... prostate cancer those with a Gleason score between ... most aggressive and rapidly growing prostate cancers. , "What ...
(Date:4/17/2014)... of the most popular vaccine brands for children may ... be overlooking some cost factors when choosing vaccines, driving ... option, according to a new study by University of ... can be driven by numerous factors," says Sheldon H. ... of computer science and of mathematics at the U. ...
(Date:4/17/2014)... University of California, San Diego School of Medicine report ... suffered a recent major loss are more likely to ... The study is published in this month,s issue of ... Because compassionate behaviors are associated with better health and ... into ways to improve the outcomes of individuals whose ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2
... , ... leaders Earn Prestigious Parallels Partner Awards for innovation, branding, inspiration and growth at the ... ... , today announced the winners of its inaugural Partner Awards at the Parallels Summit ...
... , , ... ... ... ...
... a cruel, hereditary condition that leads to severe physical and ... are no treatments to slow down or stop it. ... not show symptoms until late in life. In a ... Stephen Ferguson and Fabiola Ribeiro of Robarts Research Institute at ...
... ... a business process consultant, life coach and self improvement veteran of more ... coaches to market their services, as well as an Ask-a-Coach corner where ... of information where coaches, clients and visitors may freely interact. ...
... ... ... ... ...
... proteins in premalignant oral lesions may predict oral ... SIBLINGs, or Small Integrin-Binding Ligand N-linked Glycoproteins, ... mineralize bone but can also spread cancer. SIBLINGs ... colon and prostate. "Several years ago we ...
Cached Medicine News:Health News:Winners are Grinners at the Inaugural Parallels Partner Awards 2Health News:Winners are Grinners at the Inaugural Parallels Partner Awards 3Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 2Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 3Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 4Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 5Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 6Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 7Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 8Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 9Health News:Protecting the brain from a deadly genetic disease 2Health News:Improvement Now Made Easier With Self-Improvement-Life-Coach.com 2Health News:Improvement Now Made Easier With Self-Improvement-Life-Coach.com 3Health News:Improvement Now Made Easier With Self-Improvement-Life-Coach.com 4Health News:ChildCare Education Institute Supports the First Lady's Efforts to Reduce Childhood Obesity 2Health News:ChildCare Education Institute Supports the First Lady's Efforts to Reduce Childhood Obesity 3Health News:ChildCare Education Institute Supports the First Lady's Efforts to Reduce Childhood Obesity 4Health News:ChildCare Education Institute Supports the First Lady's Efforts to Reduce Childhood Obesity 5Health News:SIBLING proteins may predict oral cancer 2
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
(Date:1/14/2014)... 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System ... accompanying instrumentation to place and insert the screw accurately ... tissue (e.g. ligament) repair or reconstruction as it holds ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) The ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: